Left atrial appendage patency and device-related thrombus after percutaneous left atrial appendage occlusion: a computed tomography study.
Hubert Cochet, Xavier Iriart, Soumaya Sridi...
https://pubmed.ncbi.nlm.nih.gov/29415203/Actively Recruiting
Led by University Hospital, Bordeaux · Updated on 2026-06-10
60
Participants Needed
2
Research Sites
N/A
Total Duration
The APPENDAGE study is a phase 4 multicenter randomized clinical trial evaluating two antithrombotic strategies after left atrial appendage closure LAAC in patients with non-valvular atrial fibrillation AF. It aims to compare aspirin alone versus aspirin combined with clopidogrel to assess their effectiveness in preventing ischemic brain lesions, which are detected by cerebrovascular MRI scans. This research addresses the challenge of balancing bleeding risk and thromboembolic risk after LAAC, a procedure recommended for stroke prevention in AF patients who cannot use oral anticoagulation. Participants receive either aspirin plus clopidogrel or aspirin alone starting on the day of the LAAC procedure and continuing for three months. The LAAC is performed using devices such as the Watchman or Amplatzer Cardiac PlugAmulet. Brain MRI scans are performed immediately after the procedure and again at three months to detect ischemic lesions. The study also includes neurological tests like the NIH Stroke Scale, Modified Rankin Score, and Montreal Cognitive Assessment to evaluate functional and cognitive impacts. During the study, participants are monitored for neurological events, bleeding complications, device-related thrombus, and treatment adherence. Assessments occur at baseline, day 1, and month 3, including MRI, neurological tests, and evaluation of systemic and cerebral events. The primary outcome is the change in ischemic lesions on brain MRI over three months. Participant involvement includes follow-up visits for clinical and cognitive assessments, with a total study duration of three months after the LAAC procedure.
CONDITIONS
AntiPlatelet theraPy stratEgy followiNg Left Atrial appenDAGe closurE
Z
Zakaria JALAL, MD
A
Amandine RUISSEL
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University Hospital, Bordeaux
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 3 months
Participants receive either aspirin alone or aspirin plus clopidogrel starting on the day of the left atrial appendage closure and continuing for three months.
Visits and assessments at procedure day, day 1, and month 3
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Hubert Cochet, Xavier Iriart, Soumaya Sridi...
https://pubmed.ncbi.nlm.nih.gov/29415203/University Hospital, Bordeaux
Lead Sponsor